Navigation Links
Penn researchers find targeted therapy combination overcomes treatment resistance in liver cancer
Date:4/13/2008

SAN DIEGO Researchers at the University of Pennsylvania School of Medicine and Abramson Cancer Center reported today at the annual meeting of the American Association for Cancer Research that combining two targeted therapies overcomes treatment resistance in liver cancer cell lines. The team is currently designing a trial to test the combination in patients.

Liver cancer is resistant to many chemotherapies and to cell-death inducing agents. Last year, however, the U.S. Food and Drug Administration approved sorafenib (Nexavar) as a treatment for liver cancer after a clinical trial showed that the targeted agent prolonged survival in some patients.

Unfortunately not all patients respond to sorafenib and the drug does not cure the disease.

Therefore, Wafik El-Deiry, MD, PhD, Professor of Medicine, Genetics, and Pharmacology, and co-Program Leader of Radiation Biology in the Abramson Cancer Center, and colleagues have tested other targeted agents in combination with sorafenib.

They found that treating liver cancer cells with sorafenib and an antibody or the natural ligand that stimulates programmed cell death via the TRAIL pathway, dramatically increases the rate of cell death.

Sorafenib by itself causes a little cell death, but not that much, Dr. El-Deiry said. Now you combine sorafenib and TRAIL, and all of the sudden you get massive cell death. It is a real synergistic interaction. It is very profound killing.

The combination works regardless of whether the researchers use a monoclonal antibody that stimulates the TRAIL receptor, which resides on the surface of the cancer cells, or the receptors natural ligand, a small protein called TRAIL. Both the antibody and the TRAIL ligand are currently being tested as single agents in patients.

Within the next several months, Dr. El-Deirys team expects to announce the details for a trial testing the combination in patients.

In a healthy individual, the immune system uses the TRAIL pathway to rid the body of unwanted cells, including precancerous ones. Once cancer develops, however, the cells often become less responsive to TRAIL activation, in part because of an overabundance of a protein called Mcl-1, according to Dr. El-Deiry. His team found that sorafenib reduces the amount of Mcl-1 in the cancer cells, restoring their sensitivity to TRAIL-induced cell death.

Although the Penn investigators focused their current report on liver cancer, they discovered that the sorafenib-TRAIL combination also kills colon cancer cell in vitro and in animal models.


'/>"/>

Contact: Olivia Fermano
Olivia.Fermano@uphs.upenn.edu
215-349-5653
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Researchers find disparities in depression among older Hispanics in US
2. Researchers Identify New Genetic Links to Psoriasis
3. Penn researchers discover modus operandi of heart muscle protein
4. Researchers Pursuing Nasal Anthrax Vaccine
5. Researchers find mass media campaigns useful
6. Researchers pilot new electronic system for infectious illness
7. Researchers Find Gene Mutation That Increases Asthma Risk
8. Researchers Define Mechanism of Methamphetamine Addiction
9. Attacks against medical researchers: Time to take a stand
10. Researchers Able to Continue their Work to Help Patients Thanks to McDevitt Excellence in Research Awards from Blue Cross Blue Shield of Michigan Foundation
11. More genes for Lou Gehrigs disease identified, according to Penn researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... 25, 2017 , ... Somnoware, a leading provider of digital ... module. Using this new feature, sleep physicians can now predict the likelihood of ... airway pressure (CPAP), oral, or other forms of sleep apnea therapy. The Somnoware ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, at this ... joint health in horses at the immunologic level. , The scientifically-developed Flexadin UCII ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... technology yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, the ... CNS’ pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed tablet in ...
(Date:4/24/2017)... Salt Lake City, UT (PRWEB) , ... April 24, 2017 , ... ... in their efforts to encourage sustainability, innovate new strategies to reduce waste, and support ... all-natural herbal remedy provider. They look to nature to find solutions for health issues, ...
(Date:4/24/2017)... ... April 24, 2017 , ... The bar for just about everything—apparel, eyewear, ... the rarified air of pop and film stardom.(1) Not to be left out is ... smile. Grins now run the gamut from being encrusted with jewels and precious metals ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology: